MMI Co-Founder, John Hipp, PhD. to be Guest Editor for Special Issue of Bioengineering! Submit by Nov 30!
Press Release!: Driving Excellence in Cardiovascular Trials: MMI and Healthcare Inroads Deepen Collaboration
MMI Co-Founder and Chief Scientific Officer, Dr. John Hipp, PhD, has been invited to serve as the Guest Editor for an upcoming Special Issue of Bioengineering Journal!
Imaging plays a key role in patient selection for GAE treatment.
Onboarding an expert-imaging group in your clinical trials is essential for success!
Dr. Mark Schweitzer discusses a return to low-field MRI spurred on by energy demands and tech advances.
Radiographic spine fusion assessment is complicated by a lack of standardized criteria, highlighting the need for imaging expertise during clinical trials.
Dr. Mark Schweitzer, MD, expounds on design and reporting considerations for imaging assessments in research publications.
Insights from the 2022 OARSI Clinical Trials Symposium
In a research letter in Spine, MMI collaborated with researchers to investigate the SPSI as an objective measure of instability in lumbar stenosis patients with degenerative spondylolisthesis.
Since 2000, the FDA has explicitly described the importance of radiographic evaluation in spinal studies in primary and secondary endpoints.
FDA recommends using imaging of the sinuses as a secondary efficacy endpoint for drugs being developed to treat chronic rhinosinusitis with nasal polyps (CRSwNP).
Semi-automated quantitative measurements of sinus inflammation from 3D CT imaging correlate well with clinical outcomes.
Facing an aging population and unprecedented scrutiny over treatment costs, clinical trials that seek to improve treatment of late-stage conditions and diseases such as osteoarthritis are set to make a significant impact.
